Diltiazem
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Diltiazem
Diltiazem: Known uses and market status in Australia
Summary
The TxGNN model’s candidates for Diltiazem are all known uses, so there is currently no new predicted indication. The one candidate that can be traced to a source, Prinzmetal angina, is already supported by a licence in another country.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 1 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| Prinzmetal angina | licence in another country (approved indication: angina) |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 1312C | Cardizem CD | Capsule (controlled delivery) containing | Valid |
Safety Considerations
Contraindication signals from the knowledge graph (not label text): these come from drug-disease contraindication links in the TxGNN knowledge graph and should be verified against the Product Information. They include:
- Cardiac conduction and rhythm: atrioventricular block, sick sinus syndrome, Wolff-Parkinson-White syndrome, Lown-Ganong-Levine syndrome, ventricular tachycardia
- Haemodynamic and structural: hypotensive disorder, aortic stenosis, hypertrophic cardiomyopathy, renal artery obstruction
- Organ disease: kidney disease, liver disease, gallbladder disease
- Haematological: neutropenia, agranulocytosis
- Angioedema (several forms)
Several of these (atrioventricular block, sick sinus syndrome, hypotension) are especially relevant if diltiazem were used in stroke patients, who often have labile blood pressure and arrhythmias.
Drug interactions: 100 interactions were identified. Those listed in the data include:
- Major: loperamide
- Moderate: corticosteroids (hydrocortisone, dexamethasone, betamethasone, budesonide, triamcinolone), pioglitazone, bupropion, aprepitant, morphine, aspirin, canagliflozin, and calcium salts
The literature also highlights that diltiazem inhibits CYP3A4 and P-glycoprotein, which may raise DOAC levels and bleeding risk. Statin interactions (e.g. simvastatin) have also been reported. This matters because patients with cerebrovascular disease commonly take anticoagulants and statins.
Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications, as these were not available for this report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.